Comply With What? Hemp Ban Nears; the FDA Leaves Industry Waiting for Answers

The federal government has given America’s hemp industry a date: November 12, 2026. On that day, a sweeping new definition of hemp is scheduled to take effect, potentially pushing many products currently sold legally into the federal definition of marijuana. But less than three months before that deadline, the Food and Drug Administration still has not published information Congress explicitly ordered it to produce within 90 days — a deadline that expired more than six months ago.

Companies deciding what to manufacture, formulate, package and distribute are preparing for a federal standard while pieces of the government’s own compliance framework remain unpublished.

Congress Wrote the Rule. FDA Missed the Deadline.

The change comes from Section 781 of P.L. 119-37, enacted November 12, 2025.

The law replaces the familiar 0.3% delta-9 THC standard with a broader total-THC standard and excludes several categories of hemp-derived cannabinoid products. Most consequentially for finished products, anything containing more than 0.4 milligrams combined total THC and certain similar-effect cannabinoids per container would fall outside the federal definition of hemp.

The Congressional Research Service explains that products excluded from the hemp definition would instead become subject to regulation under the Controlled Substances Act as marijuana.

Congress did not simply enact that limit and walk away. It ordered FDA, in consultation with other federal agencies, to publish within 90 days three lists: cannabinoids naturally produced by cannabis; naturally occurring THC-class cannabinoids; and other cannabinoids with similar effects to — or marketed as having similar effects to — THC-class cannabinoids.

Congress also ordered FDA to provide additional information about what constitutes a “container.”

The statute provides a starting definition: essentially the innermost retail packaging that directly touches the product. But Congress explicitly demanded further specificity from FDA.

The deadline was approximately February 10.

It passed.

And according to an updated Congressional Research Service report published August 17, the required FDA material still had not been published as of August 2026.

Tell Us the Rules Before You Enforce Them

That is where regulatory dysfunction becomes a business problem.

A manufacturer can read “0.4 milligrams per container.” But companies still need the government’s promised specificity about how that definition applies across real-world product and packaging configurations. More fundamentally, operators need to know precisely which cannabinoids FDA places on the lists Congress ordered it to create.

Those aren’t academic questions when businesses must decide months in advance what products to formulate, packaging to order, inventory to manufacture, and contracts to sign.

FDA has legitimate constraints. Determining how cannabinoids should be classified requires scientific analysis, and the agency has repeatedly wrestled with how cannabis-derived products fit within its existing authorities. FDA itself told Congress in 2023 that existing regulatory frameworks were not appropriate for CBD and requested a new regulatory pathway.

But that does not change the basic accountability problem.

Congress established the rule. Congress established the deadline for industry. Congress also set a deadline for the government to provide the information needed to implement that rule.

Only one side has missed its deadline so far.

Unless Congress changes the law, November 12 keeps approaching. Hemp companies do not get to tell federal regulators that they were too busy, understaffed, or still deciding what the statute means.

The government shouldn’t get to operate as though its own deadlines are optional while industry’s are mandatory.